Thomas Dobbs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Thomas Dobbs has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
A. Cassandra Dove Brown
Mississippi State Department of Health, Jackson, Mississippi
1 shared publication- Benjamin H. Walker
John D. Bower School of Population Health University of Mississippi Medical Center Jackson Mississippi USA
1 shared publication - Bernadette E. Grayson
John D. Bower School of Population Health University of Mississippi Medical Center Jackson Mississippi USA
1 shared publication D. Trent
Georgia Cancer Specialists, Marietta, GA; University of North Carolina, Chapel Hill, NC; Virginia Cancer Institute, Richmond, VA; Tennessee Cancer Specialists, Knoxville, TN; Florida Hospital Cancer Institute, Orlando, FL; Greater Baltimore Medical Center, Baltimore, MD; Ann Arbor Hematology Oncology, Ann Arbor, MI
1 shared publicationG.C. Dane
1 shared publicationI. Hudson
1 shared publication
Latest Publications
- 23 August 2026
- Published by Wiley in Journal of Public Health Dentistry
Key Predictors of Oral Health Service Utilization Among Working‐Age Adults With and Without Depression in the United States
Objective: The study aimed to determine the key factors that predict oral health care utilization among persons with and without depression. Methods: Data from 17,525 working‐age adults from the 2022 National Health Interview Survey were analyzed. Survey‐weighted Poisson regression models estimated the population‐level associations between sociodemographic factors (e.g., income, education, last medical visit) and a report of no past‐year dental visit and Delayed Dental Care due to cost (DDC), while Random Forest (RF) permutation importance quantified each variable's contribution to predictive discrimination for individuals with or without depression. Results: The adjusted prevalence (aPR) of no past‐year dental visit and DDC was greater among those with depression compared to those without depression (39.6% vs. 35.3% aPR = 1.12; 95% confidence interval (CI), 1.06 to 1.18) and (26.6% vs. 17.8%, aPR = 1.47, 95% CI, 1.35, 1.59), respectively. Our RF models demonstrated an acceptable range of discrimination for both outcomes (AUC range: 0.67–0.73) across the subgroups by depression status. Income was the most important variable contributing most to all four models' discrimination, regardless of depression status, suggesting a cross‐cutting impact on oral health service utilization regardless of depression status. Conclusion: Individuals with depression were less likely to visit the dentist and more likely to report cost‐related delayed dental care than those without depression. Further, income was an important factor impacting oral health care‐seeking behavior.
- 23 August 2026
- Published by Wiley in Journal of Public Health Dentistry
Key Predictors of Oral Health Service Utilization Among Working‐Age Adults With and Without Depression in the United States
Objective: The study aimed to determine the key factors that predict oral health care utilization among persons with and without depression. Methods: Data from 17,525 working‐age adults from the 2022 National Health Interview Survey were analyzed. Survey‐weighted Poisson regression models estimated the population‐level associations between sociodemographic factors (e.g., income, education, last medical visit) and a report of no past‐year dental visit and Delayed Dental Care due to cost (DDC), while Random Forest (RF) permutation importance quantified each variable's contribution to predictive discrimination for individuals with or without depression. Results: The adjusted prevalence (aPR) of no past‐year dental visit and DDC was greater among those with depression compared to those without depression (39.6% vs. 35.3% aPR = 1.12; 95% confidence interval (CI), 1.06 to 1.18) and (26.6% vs. 17.8%, aPR = 1.47, 95% CI, 1.35, 1.59), respectively. Our RF models demonstrated an acceptable range of discrimination for both outcomes (AUC range: 0.67–0.73) across the subgroups by depression status. Income was the most important variable contributing most to all four models' discrimination, regardless of depression status, suggesting a cross‐cutting impact on oral health service utilization regardless of depression status. Conclusion: Individuals with depression were less likely to visit the dentist and more likely to report cost‐related delayed dental care than those without depression. Further, income was an important factor impacting oral health care‐seeking behavior.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
445. An Ongoing Battle from a Forgotten War: Long COVID in Mississippi, October 2021 - September 2022
Due to the lack of a well-established definition, long COVID—unlike its acute counterpart—has been evading statewide surveillance systems. In October 2021, however, the adoption of an ICD-10-CM code for long COVID, created the prerequisite needed for such retrospective state-level surveillance of long COVID. To seize this opportunity and establish baseline information, we used Mississippi’s hospital discharge data to examine hospitalizations associated with long COVID. Hospital discharge data are a population-level data source that captures data from all non-federal hospitals in the state and contains information on diagnoses, procedures, and resource utilization. In this cross-sectional study, we utilized the latest available data that incorporates long COVID diagnoses (10/01/2021-09/30/2022). The study included only adult Mississippi residents (≥ 18 years) and the unit of analysis was individual patients. We performed descriptive and inferential (chi-squared tests) statistical analyses. Among the 1,213 patients hospitalized with post-COVID-19 complications, the majority were white (69.7%), elderly (average age = 66), rural residents (60.3%), and females (53.8%). The most common comorbidities were hypertension (73.6%), diabetes (39.4%), chronic pulmonary disease (28.4%), and congestive heart failure (28.4%). Among long haulers, 22.1% were admitted to ICU, 13.6% needed respiratory support, and 8.5% died in the hospital. The in-hospital mortality proportion among long haulers did not differ by race, residence, or insurance status. In-hospital deaths were more likely to occur, however, among patients ≥ 65 years (68.7% vs. 56.3%, p < .01). Compared to survivors, deceased patients with long COVID had a slightly higher average number of comorbid conditions (2.8 vs. 2.2). For patients with long COVID, the mean length of stay was 11 days and the mean hospital charges were $109,739. In our study, we identified that hypertension was highly prevalent among long haulers. The severity of illness as measured by ICU care, in-hospital mortality, length of stay, and hospital charges was also high among patients with long COVID. These findings underscore the importance of long-term surveillance of COVID-19 complications. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access445. An Ongoing Battle from a Forgotten War: Long COVID in Mississippi, October 2021 - September 2022
Due to the lack of a well-established definition, long COVID—unlike its acute counterpart—has been evading statewide surveillance systems. In October 2021, however, the adoption of an ICD-10-CM code for long COVID, created the prerequisite needed for such retrospective state-level surveillance of long COVID. To seize this opportunity and establish baseline information, we used Mississippi’s hospital discharge data to examine hospitalizations associated with long COVID. Hospital discharge data are a population-level data source that captures data from all non-federal hospitals in the state and contains information on diagnoses, procedures, and resource utilization. In this cross-sectional study, we utilized the latest available data that incorporates long COVID diagnoses (10/01/2021-09/30/2022). The study included only adult Mississippi residents (≥ 18 years) and the unit of analysis was individual patients. We performed descriptive and inferential (chi-squared tests) statistical analyses. Among the 1,213 patients hospitalized with post-COVID-19 complications, the majority were white (69.7%), elderly (average age = 66), rural residents (60.3%), and females (53.8%). The most common comorbidities were hypertension (73.6%), diabetes (39.4%), chronic pulmonary disease (28.4%), and congestive heart failure (28.4%). Among long haulers, 22.1% were admitted to ICU, 13.6% needed respiratory support, and 8.5% died in the hospital. The in-hospital mortality proportion among long haulers did not differ by race, residence, or insurance status. In-hospital deaths were more likely to occur, however, among patients ≥ 65 years (68.7% vs. 56.3%, p < .01). Compared to survivors, deceased patients with long COVID had a slightly higher average number of comorbid conditions (2.8 vs. 2.2). For patients with long COVID, the mean length of stay was 11 days and the mean hospital charges were $109,739. In our study, we identified that hypertension was highly prevalent among long haulers. The severity of illness as measured by ICU care, in-hospital mortality, length of stay, and hospital charges was also high among patients with long COVID. These findings underscore the importance of long-term surveillance of COVID-19 complications. All Authors: No reported disclosures
- Open Access
- 17 September 2020
- Published by Centers for Disease Control and Prevention (CDC) in Preventing Chronic Disease
- Vol. 17
The Mississippi Delta Health Collaborative Medication Therapy Management Model: Public Health and Pharmacy Working Together to Improve Population Health in the Mississippi Delta
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.
- 17 September 2020
- Published by Centers for Disease Control and Prevention (CDC) in Preventing Chronic Disease
- Vol. 17
Open AccessThe Mississippi Delta Health Collaborative Medication Therapy Management Model: Public Health and Pharmacy Working Together to Improve Population Health in the Mississippi Delta
Preventing Chronic Disease (PCD) is a peer-reviewed electronic journal established by the National Center for Chronic Disease Prevention and Health Promotion. PCD provides an open exchange of information and knowledge among researchers, practitioners, policy makers, and others who strive to improve the health of the public through chronic disease prevention.
- 20 June 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18_suppl) , 7586
Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC)
7586 Background: Cetuximab, an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR) on both normal and tumor cells, has been investigated in advanced NSCLC as a single agent and in combination with chemotherapy. This ongoing randomized phase II open-label trial evaluates cetuximab in combination with carboplatin (Cb) and paclitaxel (Pac) when given in two dose schedules to patients (pts) with previously untreated stage IIIB/IV NSCLC. Methods: Eligible pts were randomized to 1 of 2 treatment arms. Cetuximab treatment was identical in both arms: 400 mg/m2 IV on day 1 and 250 mg/m2 weekly thereafter. Beginning on day 8, a schedule of Cb AUC=6 IV and Pac 225 mg/m2 IV given on a 3-week cycle was compared with a schedule of Cb AUC=6 IV q4 weeks and Pac 100 mg/m2 IV given weekly for 3 weeks of each 4-week cycle. Pts who achieve CR, PR, or SD after 4 cycles may continue weekly cetuximab monotherapy until disease progression or unacceptable toxicity. The primary objectives were to estimate median progression-free survival (PFS) and the PFS rate at 6 months. Secondary objectives included response rate. Results: The study has completed accrual, with 168 pts randomized and 165 treated. Data are available for 164 pts and confirmed responses for 155 pts. Conclusions: Cetuximab combined with Cb and Pac in both dose schedules demonstrated activity and an acceptable toxicity profile in pts with NSCLC. Final PFS and overall survival data are pending. No significant financial relationships to disclose.
- 20 June 2007
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (18_suppl) , 7586
Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC)
7586 Background: Cetuximab, an IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR) on both normal and tumor cells, has been investigated in advanced NSCLC as a single agent and in combination with chemotherapy. This ongoing randomized phase II open-label trial evaluates cetuximab in combination with carboplatin (Cb) and paclitaxel (Pac) when given in two dose schedules to patients (pts) with previously untreated stage IIIB/IV NSCLC. Methods: Eligible pts were randomized to 1 of 2 treatment arms. Cetuximab treatment was identical in both arms: 400 mg/m2 IV on day 1 and 250 mg/m2 weekly thereafter. Beginning on day 8, a schedule of Cb AUC=6 IV and Pac 225 mg/m2 IV given on a 3-week cycle was compared with a schedule of Cb AUC=6 IV q4 weeks and Pac 100 mg/m2 IV given weekly for 3 weeks of each 4-week cycle. Pts who achieve CR, PR, or SD after 4 cycles may continue weekly cetuximab monotherapy until disease progression or unacceptable toxicity. The primary objectives were to estimate median progression-free survival (PFS) and the PFS rate at 6 months. Secondary objectives included response rate. Results: The study has completed accrual, with 168 pts randomized and 165 treated. Data are available for 164 pts and confirmed responses for 155 pts. Conclusions: Cetuximab combined with Cb and Pac in both dose schedules demonstrated activity and an acceptable toxicity profile in pts with NSCLC. Final PFS and overall survival data are pending. No significant financial relationships to disclose.
- 1 August 1997
- Published by Elsevier in Lung Cancer
- Vol. 18, 13-14
41 Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC)
- 1 August 1997
- Published by Elsevier in Lung Cancer
- Vol. 18, 13-14
41 Preliminary results of a randomized comparative phase III trial of topotecan (T) versus CAV as second-line therapy of small cell lung cancer (SCLC)